Seok-Jin Kim; Jiyeon Hyeon; Inju Cho; Young Hyeh Ko; Won Seog Kim

doi:10.4143/crt.2018.191

Articles

Page Path: HOME > Cancer Res Treat > Volume 51(2); 2019 > Article

Original Article Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas: Seok-Jin Kim, MD, PhD¹, Jiyeon Hyeon, MD, PhD², Inju Cho, MD², Young Hyeh Ko, MD, PhD², Won Seog Kim, MD, PhD¹; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2019;51(2):611-622.
DOI: https://doi.org/10.4143/crt.2018.191
Published online: July 20, 2018

¹Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

²Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Correspondence: Won Seog Kim, MD, PhD Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea
Tel: 82-2-3410-6548 Fax: 82-2-3410-1754 E-mail: wskimsmc@skku.edu

^*Seok-Jin Kim and Jiyeon Hyeon contributed equally to this work.

• Received: April 2, 2018 • Accepted: July 17, 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

17,166 Views
633 Download
81 Web of Science
75 Crossref
93 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
Pembrolizumab, a programmed cell death protein 1 (PD1) inhibitor inhibits the interplay between PD1 of T-cell and programmed cell death ligand 1 (PDL1) on tumor cells. Although pembrolizumab has been tried to various subtypes of non-Hodgkin lymphoma (NHL), real-world data about the efficacy of pembrolizumab in NHL patients are limited.
Materials and methods
We analyzed the outcome of 30 relapsed or refractory NHL patients treated with pembrolizumab, and compared the outcome between Epstein-Barr virus (EBV)‒positive and negative subtypes because EBV infection of tumor cells can upregulate PDL1 expression.
Results
Seven patients with EBV-positive NHL showed a response including NK/T-cell lymphoma (6/14, 44%) and primary mediastinal B-cell lymphoma (1/4, 25%) whereas EBV-negative subtypes did not respond such as diffuse large B-cell lymphoma and T-lymphoblastic lymphoma. We also evaluated PDL1 expression using tumor tissue of 76 patients. High PDL1 expression (positive staining of > 50% of tumor cells) was more frequent in NK/T-cell lymphoma and primary mediastinal B-cell lymphoma than other subtypes. Thus, PDL1 expression was significantly higher in EBV-positive (18/32, 56%) than EBV-negative NHL (4/38, 11%, p < 0.001). Furthermore, NK/T-cell lymphoma patients with high PDL1 expression showed a higher response (4/6, 67%) than those with low PDL1 expression (1/5, 20%).
Conclusion
Pembrolizumab could be useful as a salvage treatment for relapsed or refractory EBV-positive NHL, especially NK/T-cell lymphoma. However, its efficacy in EBV-negative NHL with low or absent PDL1 expression is still not clear although pembrolizumab could be a potential treatment option for relapsed or refractory NHL.
Key words: Lymphoma, Pembrolizumab, PDL1, Epstein-Barr virus

Introduction

Non-Hodgkin lymphoma (NHL) represents a heterogeneous group of malignancies with distinct clinical and pathological features. New treatments have improved the outcomes of NHL, but a substantial number of patients still relapse and require multiple treatments because only a limited number of patients respond to salvage treatment and the response is usually of short duration [1,2]. Furthermore, as intensified salvage chemotherapy is repeated, treatment-related toxicity contributes to long-term morbidity and poor survival outcomes. Thus, there is an unmet need for more effective and less toxic drugs for the treatment of NHL. Recent improvements in the understanding of the evasion of the immune response by tumor cells have led to the identification of immune checkpoint inhibition as a new tool for cancer treatment [3]. The programmed cell death protein 1 (PD1) is an immune checkpoint that regulates the host immune response. The binding of PD1 ligand 1 (PDL1) on tumor cells to PD1 on the surface of effector T-cells transduces inhibitory signals to the T cells, allowing tumor cells to escape antitumor immunity [4]. Therefore, inhibition of this interplay between PD1 and PDL1 can reverse this immune escape and enhance T-cell cytotoxicity against tumor cells. Currently, two monoclonal IgG4 anti-PD1 antibodies, nivolumab and pembrolizumab, are approved by the Food and Drug Administration (FDA) as salvage treatment for solid cancers such as melanoma and non-small cell lung cancer. The FDA has also granted accelerated approval to nivolumab and pembrolizumab for the treatment of relapsed or refractory classical Hodgkin lymphoma (HL). However, data concerning the use of pembrolizumab in patients with NHL are limited because its efficacy in relapsed or refractory NHL has not been determined. In our institute, we have used pembrolizumab to treat patients with various subtypes of relapsed or refractory NHL, and already reported the exciting outcome of one patient with relapsed NK/T-cell lymphoma (NKTCL) in a previous multicenter retrospective study [5]. Since January 2016, we have used pembrolizumab as a salvage treatment for thirty patients with relapsed or refractory NHL. In this study, we retrospectively analyzed their treatment outcome to illustrate our real-world experience with pembrolizumab treatment in relapsed or refractory NHL outside of clinical trials.

Materials and Methods

1. Patients and treatment

Thirty consecutive patients with relapsed or refractory NHL were treated with pembrolizumab at the Samsung Medical Center between January 2016 and September 2017. Informed consent for the use of pembrolizumab was obtained from all patients. Because the cost of pembrolizumab is not reimbursed by health insurance in Korea, a fixed low dose of 100 mg was administered to 27 patients while three patients received the recommended dose of 200 mg. The treatment cycle was repeated every 3 weeks. The response was assessed using 2-deoxy-2-fluorine-18-fluoro-D-glucose positron emission tomography integrated with computed tomography and computed tomography according to standard criteria. In most patients, the first response evaluation was performed after the second or third cycle of treatment [6]. If signs of rapid deterioration were observed, response evaluation was performed earlier than the planned date. For patients with NKTCL, blood Epstein–Barr virus (EBV) DNA titer was also quantified as previously reported as an indirect biomarker of the extent of disease [7].

2. Assessment of PDL1 expression in NHL

We assessed PDL1 expression of tumor cells by immunohistochemistry (IHC) to evaluate the extent of PDL1 expression in various subtypes of NHL. Thus, PDL1 expression was assessed in relapsed or refractory NHL patients (n=76) for whom paraffin-embedded tissue blocks were available for IHC. Most tissue samples were from archived tissue samples in our lymphoma registry that were obtained as routine clinical practice at the time of diagnosis (n=71), and only five cases were from obtained at relapse or progression. After IHC, we analyzed the proportion of cells in each tumor subtype that expressed PDL1 to determine whether PDL1 expression differed according to subtype of NHL. We also evaluated the EBV positivity of tumor cells, correlating the results of EBV in situ hybridization with PDL1 expression for each subtype of NHL. These 76 patients included 21 patients treated with pembrolizumab who were analyzed for response evaluation. Thus, we could evaluate the PDL1 expression of tumor cells in patients receiving pembrolizu-mab to determine whether the response to pembrolizumab was correlated with PDL1 expression.

3. IHC for PDL1 and EBV positivity

Two assays including monoclonal antibodies against PDL1 were used: the Ventana PDL1 (SP142) assay (1:25, rabbit antihuman PDL1/CD274 monoclonal antibody, clone SP142, Ventana, Tucson, AZ) and the PDL1 IHC 22C3 pharmDx assay, which includes the murine 22C3 anti-human PDL1 antibody (Dako, Carpinteria, CA). PDL1 IHC using the Ventana PDL1 assay was performed on an automated immunostainer (Benchmark, Ventana) according to the manufacturer’s instructions. In some cases, PDL1 IHC was performed using the PDL1 IHC 22C3 pharmDx kit using a Link 48 autostainer according to the manufacturer’s instructions. Because it was difficult to identify tumor cells precisely when observing only hematoxylin and eosin (H&E) stained slides, PDL1 expression on tumor cells was investigated by comparing H&E slides. The proportion of PDL1-positive cells was estimated as a percentage of total tumor cells; tumor cells typically showed membranous staining with a variable component of cytoplasmic staining. The percentage of tumor cells positively stained for PDL1 was determined by pathologists. Because there are no established criteria for high PDL1 expression in lymphoma, we used the cutoff value of 50% which was suggested by the manufacturer’s instructions of PDL1 IHC 22C3 pharmDx kit [8]. Thus, PDL1 expression was defined as follows: No expression (PDL1-positive tumor cells < 1%), low expression (PDL1-positive tumor cells 1%-49%), and high expression (PDL1-positive tumor cells ≥ 50%).

4. Study parameters

The response of each patient was classified based on the best response during pembrolizumab treatment, regardless of the final outcome. The overall response rate (ORR) was based on the number of patients who achieved a complete response (CR) or a partial response (PR). The toxicity profiles of pembrolizumab were determined based on review of the medical records. The number of previous treatments was defined as the total number of cycles of treatment from the first-line chemotherapy to the last chemotherapy before pembrolizumab. Radiotherapy or autologous or allogeneic stem cell transplantation (SCT) were not included in the number of previous treatments because they were used as adjuvant or consolidation therapy. The characteristics of patients including age, performance status, stage, and absolute lymphocyte count were recorded at the time of pembrolizumab treatment, not at the time of diagnosis. Time to pembrolizumab was defined as the interval between the date of diagnosis and the date of the first infusion of pembrolizumab. Post-pembrolizumab survival was defined as the time between the date of first infusion of pembrolizumab and the date of last follow-up or death from any cause. The participants’ disease status and survival were updated on December 31, 2017.

5. Ethical statement

The study was approved by the Institutional Review Board of Samsung Medical Center (IRB No. 2017-11-105) and performed in accordance with the principles of the Declaration of Helsinki. The informed consent was waived.

Results

1. Characteristics of patients before pembrolizumab

The median age of patients at the time of pembrolizumab treatment was 49 years (range, 18 to 80 years) and most were men (n=27). The histologic subtypes of tumor were diffuse large B-cell lymphoma (DLBCL; n=10), primary mediastinal large B-cell lymphoma (PMBCL; n=4), NKTCL (n=14), and T-cell lymphoblastic lymphoma (T-LBL; n=2). Most patients had stage IV disease (n=26) with widespread organ involvement (≥ 2 sites of extranodal involvement, n=25) (Table 1). The majority of patients had been heavily treated before pembrolizumab treatment: the median number of previous chemotherapy treatments excluding SCT was 4 (range, 1 to 10), and 16 patients had undergone autologous or allogeneic SCT (Table 1). Five patients had relapsed after allogeneic SCT, including one patient who underwent haploidentical SCT. All patients with DLBCL and T-LBL showed negativity for EBV whereas all cases of NKTCL and one case of PMBCL were positive for EBV (Table 1).

2. Response to pembrolizumab

All patients with DLBCL rapidly progressed during pembrolizumab treatment and died. Therefore, more than half the patients discontinued pembrolizumab after their first cycle (median number of cycle, 1; range, 1 to 4). The two patients with T-LBL had relapsed after haploidentical and unrelated allogeneic SCT and received pembrolizumab as a salvage treatment. However, their disease rapidly progressed after the first of second cycle of pembrolizumab. Of the four patients with PMBCL, case 1 showed a PR, and completed the 12th cycles of pembrolizumab (Fig. 1). She is currently in the state of ongoing treatment. On the contrary to other tumor subtypes, six NKTCL patients responded (5 CR, 1 PR; ORR, 44%). Case 1 who had relapsed after unrelated allogeneic SCT, showed a CR: this case was included in a previous study [5]. Since then, he has continued to receive pembrolizumab up to 16 cycles, and has shown no clinical or radiologic evidence of disease relapse during treatment (Fig. 1). Case 2, an 80-year-old man who was diagnosed with stage IV NKTCL only received a half-dose of SMILE (steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide) chemotherapy because he was elderly and unsuitable for intensified chemotherapy. After his third cycle of SMILE chemotherapy, his disease progressed with an elevation in blood EBV DNA titer (90,568 copies/mL). However, he achieved CR with an undetectable level of blood EBV DNA after the third cycle of pembrolizumab and completed 12 cycles. Three patients (case 3-5) also continued to receive pembrolizumab up to 19th cycle (Fig. 1). Case 6 showed a PR after the second cycle of pembrolizumab, but the patient refused further treatment for financial reasons; his disease progressed, and he died (Fig. 1). Most patients who showed disease progression after one to three cycles of pembrolizumab died.

3. Adverse events during pembrolizumab treatment

Case 1 with NKTCL developed a grade II skin rash after the third cycle of pembrolizumab treatment. The biopsy of skin lesion showed hydropic degeneration and basal vacuolization consistent with graft-versus-host disease (GVHD). Although the time to onset of skin lesion was longer than 1 year because he underwent allogeneic SCT from a matched unrelated donor 10.6 months before pembrolizumab treatment, we reported this event as an acute GVHD in a previous study [5]. The reason was that he did not have any sign of acute GVHD before pembrolizumab and his skin manifestation was not consistent with chronic GVHD. His skin lesions improved with corticosteroid treatment and further therapy was unhindered. In contrast, cases 1 and 2 with T-LBL did not develop any sign of GVHD despite having undergone haploidentical and unrelated allogeneic SCT 11.0 and 6.2 months before pembrolizumab treatment. Case 9 with NKTCL involving the small intestine developed bowel perforation after the first cycle of pembrolizumab and died as a result of sepsis (Fig. 1).

4. Association of PDL1 with EBV positivity

PDL1 expression was evaluated in archived tumor tissue samples from 76 patients with NHL including 21 patients treated with pembrolizumab. The proportion of tumors with high PDL1 expression differed according to the subtype of NHL. Thus, high PDL1 expression was more frequent in NKTCL (15/28, 54%), PMBCL (4/6, 67%), and peripheral T-cell lymphoma (PTCL; 2/7, 29%) than in DLBCL (2/18, 11%) and T-LBL (0/8, 0%). Although the numbers were small, high PDL1 expression was observed in subcutaneous panniculitis-like T-cell lymphoma and angioimmunoblastic T-cell lymphoma unlike primary central nervous system (CNS) DLBCL (0/3), mantle cell lymphoma (0/2), and enteropathy-associated T-cell lymphoma (0/1) (Fig. 2A). Although six patients were not evaluated for EBV in situ hybridization including DLBCL (n=4) and PMBCL (n=2), EBV-positivity was more frequent in NKTCL (28/28, 100%) and PTCL (3/7, 43%) than other subtypes. EBV-positive NHL included a significantly higher proportion of tumors with high PDL1 expression (18/32, 56%) compared with EBV-negative NHL (4/38, 11%, p < 0.001) (Fig. 2B). Thus, these results suggest the association of EBV-positivity with PDL1 expression although EBV-positivity was not evaluated in four cases of high PDL1 expression due to lack of available tissue (DLBCL and PMBCL) (Fig. 2A).

5. Association of PDL1 and EBV positivity with treatment outcome

When we dichotomized 30 patients receiving pembrolizumab into two groups according to the EBV positivity, seven patients with EBV-positive tumor responded to pembrolizumab (7/15) whereas all patients with EBV-negative tumor failed to respond (0/15) (Table 2). Thus, NKTCL (6/14, 44%) and PMBCL (1/4, 25%) showed higher ORR than DLBCL (0/10, 0%) and T-LBL (0/2, 0%). This higher response to pembrolizumab was associated with more frequent expression of PDL1 in EBV-positive tumors. Indeed, aforementioned case 1 of PMBCL who had EBV-positive disease and high PDL1 expression showed a PR to pembrolizumab (Fig. 1). The different proportions of high PDL1 expression in different subtypes of NHL tumors correlated with their response to pembrolizumab. Of 21 pembrolizumab-treated patients whose PDL1 expression was analyzed, five cases with high PDL1 expression responded to pembrolizumab (5/10, 50%) whereas only two cases with low PDL1 expression responded (2/11, 18%); however, this difference was not significant (p=0.183). Even in patients with NKTCL, the ORR was different between those with high (4/6, 67%) and low PDL1 expression (1/5, 20%). For example, case 6 of NKTCL with high PDL1 expression showed a PR with undetectable levels of EBV DNA in blood after pembrolizumab treatment (Fig. 3A), whereas case 10 with low PDL1 expression did not respond (Fig. 3B). However, this difference of response based on PDL1 expression could not be statistically analyzed due to small number of patients.

Discussion

In our study, pembrolizumab was used in different NHL subtypes, and their response to pembrolizumab was different. Thus, the ORR of NKTCL (6/14, 44%) was higher than that of PMBCL (1/4, 25%), DLBCL (0/10, 0%), or T-LBL (0/2, 0%). Although the number of patients in each subtype was small, our findings are consistent with those of a previous case series reporting outstanding outcomes of pembrolizumab treatment in NKTCL patients (Table 3). Actually, pembrolizumab as an off-label treatment for relapsed or refractory T- or NK-cell NHL achieved CR [5,9,10]. Of the patients with PMBCL, case 1 who was EBV positive with high PDL1 expression responded to pembrolizumab (Fig. 1). However, the other three patients with PMBCL, including one patient with high PDL1 expression, failed to respond. In a previous phase 1b study, the ORR to pembrolizumab was 41% (7/17) in relapsed or refractory PMBCL [11]. Although our response rate in PMBCL was inferior to these phase 1b results, the number of patients in our study was too small to draw definite conclusions about the efficacy of pembrolizumab in PMBCL. On the other hand, a recent phase II study using pembrolizumab plus rituximab reported 80% of ORR in relapsed or refractory follicular lymphoma [12]. This suggests the role of pembrolizumab as a combination treatment with other drugs. Indeed, a patient with double-hit lymphoma receiving pembrolizumab and lenalidomide achieved CR [13]. In our study, although not all patients responded to pembrolizumab, six cases of NKTCL did respond. Therefore, given that NKTCL usually follows an aggressive clinical course after relapse and there is currently no effective salvage treatment for NKTCL, our findings suggested that pembrolizumab could be a useful treatment option for relapsed or refractory NKTCL.

This different response of different NHL subtypes to pembrolizumab could be related to their different levels of PDL1 expression. Thus, our study analyzed the extent of PDL1 expression in 76 patients with NHL including 21 patients who received pembrolizumab. The frequency of high PDL1 expression was very rare in patients with DLBCL (2/18, 11%) and mantle cell lymphoma (0/2, 0%) in our study. Previous studies also reported the absence of PDL1 expression in mantle cell lymphoma [14,15]. Although those studies showed higher frequency of PDL1 expression in DLBCL than that of our study, it might be related with low cutoff value (5%) for PDL1 expression (Table 4). Actually, a study analyzing 1,253 patients with DLBCL showed the same incidence of PDL1 expression (132/1,253, 11%) as ours and the study used 30% of cutoff value [16]. Thus, the poor response to pembrolizumab in DLBCL patients of our study could be explained the low frequency of PDL1 expression. The main mechanism of PDL1 overexpression was amplification of chromosome 9p24.1, and is commonly observed in patients with HL [17]. However, the rearrangement of 9p24.1 leading to PDL1 overexpression was more frequently found in PMBCL and primary CNS DLBCL [18,19]. Our study also showed frequent PDL1 expression in PMBCL comparable to that of previous studies [14,15]. However, three cases of primary CNS DLBCL showed no expression of PDL1 unlike a previous study reporting 38% in Western patients [20]. This might be related with ethnic difference as well as a different cutoff value (50% vs. 1%). Thus, it should be evaluated in the future study using a larger study population. Our study showed high PDL1 expression in more than 50% of patients with NKTCL, and previous studies also reported high frequency of PDL1 expression [21,22]. This could be related with that tumor cells of NKTCL are invariably infected with EBV because EBV infection of tumor cells and activation of the inflammation-related JAK/STAT pathway also could upregulate PDL1 expression [24]. Other subtypes of NHL also had EBV-positive tumor cells although its frequency was lower than NKTCL. The frequency of EBV-positivity was known as approximately 10% in DLBCL, thus, some cases of EBV-positive DLBCL might have PDL1 expression [16]. However, considering poor response to pembrolizumab in DLBCL patients, even in case of high PDL1 expression, pembrolizumab should be very cautiously used in DLBCL patients (Fig. 1). Thus, it should be determined whether PDL1 is expressed on lymphoma cells before pembrolizumab treatment is initiated. Although only two patients with T-LBL received pembrolizumab, it cannot be recommended for this disease entity because PDL1 expression is absent in T-LBL. Overall, these results suggest that PDL1 expression on lymphoma cells might be useful as a biomarker predicting the response to pembrolizumab.

However, our study has several limitations as follows. First, we defined high PDL1 expression based on the cutoff value of 50% because there are no established criteria for high PDL1 expression in lymphoma. Thus, the frequency of high PDL1 expression in lymphoma patients might become different according to the cutoff values. However, a previous study for the development of a companion diagnostic PDL1 IHC assay for pembrolizumab therapy in non-small-cell lung cancer (NSCLC) showed the treatment effect of pembrolizumab was substantial in patients with ≥ 50% of PDL1-postitive tumor cells [25]. Furthermore, a phase III trial with pembrolizumab for NSCLC also reported a significant association of longer survival outcome with PDL1 expression on at least 50% of tumor cells [26]. Therefore, our cutoff value could be used to define high PDL1 expression in lymphoma although further studies with a larger study population should be performed to determine the correlation of response to pembrolizumab with PDL1 expression in lymphoma patients. Second, we used two types of antibodies to assess PDL1 expression. This might influence the results of PDL1 expression in our study. However, our pathology confirmed no difference of efficacy in analyzing the PDL1 expression between two types of assay. Furthermore, given the range of low and high PDL1 expression was wide (1%-49% vs. ≥ 50%), the use of two types of IHC assay might not complicate interpretation of IHC results. Third, most tissues samples for PDL1 expression were obtained from the time of diagnosis. Considering PDL1 expression might be different between diagnosis and relapse/progression, some patients showing the discrepancy of response and PDL1 expression might be associated with this limitation. Fourth, a substantial number of patients discontinued to receive pembrolizumab due to disease progression in our study (Fig. 1). Although it could be interpreted as a lack of efficacy in those patients, the probability of atypical response patterns mimicking disease progression could exist because immune-reaction inducing tumor-flare or pseudoprogression could be found in the treatment with pembrolizumab in other solid tumors. Thus, response evaluation and the assessment of disease status should be more careful in lymphoma patients receiving pembrolizumab as the refinement of the Lugano Classification Response Criteria for Lymphoma was proposed in the era of therapy with immune checkpoint inhibitor [27]. Fifth, the number of each subtype was small, especially T-LBL, and there is lack of data about the outcome of other subtypes such as mantle cell lymphoma. Thus, future study with a larger study population including more subtypes should be warranted. Lastly, the dosage of pembrolizumab given to most patients (100 mg every 3 weeks) was lower than that recommended (200 mg every 3 weeks). However, in our study the efficacy of treatment with pembrolizumab was comparable with those reported in previous studies (Table 2), and was consistent with the results of a study suggesting that low-dose pembrolizumab (100 mg every 3 weeks) could be effective for relapsed or refractory HL, with minimal toxicity [28]. In fact, when using this low dose of pembrolizumab we observed six responders (2 CR, 4 PR) out of eight patients with relapsed or refractory HL who failed treatment with brentuximab vedotin and autologous SCT (ORR, 75%) (S1 Table). The outcome of our low-dose treatment was comparable to that of previous phase II studies of relapsed or refractory HL that reported an ORR of 65% (16% CR) using 10 mg/kg of pembrolizumab every 2 weeks [29] and an ORR of 69% (22.4% CR) using 200 mg of pembrolizumab every 3 weeks [30].

None of the patients in our study showed any grade 3 or 4 hematologic or nonhematologic toxicities, and their causes of death were related to disease progression. Although one patient developed a bowel perforation, that patient had previously experienced bowel perforation during salvage chemotherapy before initiation of pembrolizumab treatment. Therefore, the toxicity of pembrolizumab was manageable, which might be because we used a low dose of 100 mg of pembrolizumab every 3 weeks, although a previous study using 10 mg/kg of pembrolizumab every 2 weeks reported five cases of grade 3 drug-related adverse events (16%). Furthermore, five patients in our study had undergone unrelated or haploidentical allogeneic SCT before receiving pembrolizumab, but only one patient developed grade II acute GVHD (case 1 with NKTCL) (Fig. 1). This might be related to the lower dose of pembrolizumab and be consistent with the safety of PD1 blockade after allogeneic SCT [10].

In conclusion, pembrolizumab could be useful as a salvage treatment for relapsed or refractory EBV-positive NHL, especially NKTCL. However, its efficacy in EBV-negative NHL with low or absent PDL1 expression is still not clear although pembrolizumab could be a potential treatment option for relapsed or refractory NHL.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (http://www.e-crt.org).

crt-2018-191-suppl1.pdf

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

This study was supported by a grant from the Basic Science Research Program through the National Research Foundation of Korea (NRF), which is funded by the Ministry of Education, Science, and Technology (NRF-2017R1A2B4005136). We also give thanks to all colleagues for participating in the research, and express our gratitude to the 20-20 project of the Samsung Medical Center.

Fig. 1.

Clinical outcome and treatment cycles of NK/T-cell lymphoma (NKTCL), primary mediastinal B-cell lymphoma (PMBCL), diffuse large B-cell lymphoma (DLBCL), and T-lymphoblastic lymphoma (T-LBL). EBV, Epstein-Barr virus; PDL1, programmed cell death ligand 1; H, high; CR, complete response; NA, not available; L, low; PR, partial response; PD, progressive disease.

Fig. 2.

(A) Comparison of programmed cell death ligand 1 (PDL1) expression in 76 patients with non-Hodgkin lymphoma shows different frequencies of high (≥ 50% of PDL1-positive tumor cells), low (1%-49% of PDL1-positive tumor cells), and no expression. High PDL1 expression is more frequent in NK/T-cell lymphoma (NKTCL; 15/28, 54%) and primary mediastinal B-cell lymphoma (PMBCL; 4/6, 67%) than in peripheral T-cell lymphoma (PTCL; 2/7, 28%), diffuse large B-cell lymphoma (DLBCL; 2/18, 11%), and T-lymphoblastic lymphoma (T-LBL; 0/8, 0%). No case of PDL1 high expression is observed in primary central nervous system diffuse large B-cell lymphoma (CNS DLBCL; 0/3), mantle cell lymphoma (MCL, 0/2), or enteropathy-associated T-cell lymphoma (EATL; 0/1). However, subcutaneous panniculitis-like T-cell lymphoma (SPTCL; 2/2) and angioimmunoblastic T-cell lymphoma (AITL; 1/1) show high PDL1 expression. (B) Epstein-Barr virus (EBV)–positive non-Hodgkin lymphoma (NHL) shows a significantly higher proportion of high PDL1 expression (18/32, 56%) than EBV-negative NHL (4/38, 11%, p < 0.001).

Fig. 3.

(A) Immunohistochemistry for programmed cell death ligand 1 (PDL1) shows ≥ 50% of tumor cells positively stained (brown membranous staining) in a case of extranodal NK/T-cell lymphoma (top left); decrease in blood Epstein-Barr virus (EBV) DNA level after pembrolizumab treatment (top right); decrease in fluorodeoxyglucose (FDG) uptake in liver and spleen after pembrolizumab treatment (bottom). (B) Immunohistochemistry for PDL1 shows < 1% of tumor cells positively stained in a case of extranodal NK/T-cell lymphoma (top left); increase in blood EBV DNA level even after pembrolizumab treatment (top right); increase in the extent and intensity of FDG uptake in a soft tissue mass in an extremity after pembrolizumab treatment (bottom).

Table 1.

Clinical characteristics of patients at the time of pembrolizumab treatment

	Total (n=30)	DLBCL (n=10)	PMBCL (n=4)	NKTCL (n=14)	T-LBL (n=2)
Age (yr)
≤ 60	22	7	4	9	2
> 60	8	3	0	5	0
Sex
Male	21	7	1	11	2
Female	9	3	3	3	0
Performance status
ECOG 0/1	9	1	3	4	1
ECOG ≥ 2	21	9	1	10	1
Stage
I/II	2/2	0/0	1/1	2	0
III/IV	0/26	0/10	0/2	12	2
No. of extranodal involvements
0/1	5	1	2	2	0
≥ 2	25	9	2	12	2
Serum LDH
Normal	10	2	1	5	0
Increased	20	8	3	9	2
IPI
Low/Low-intermediate	4/2	0/1	2/0	2/0	0/1
High-intermediate/High	8/16	1/8	1/1	5/7	1/0
No. of previous treatments, median (range)	4 (1-10)	5 (2-10)	4 (3-6)	3 (1-7)	2 (2-3)
Previous SCT	14	3	2	6	2
Autologous	9	3	2	4	0
Allogeneic	4	0	0	2	1
Both	1	0	0	0	1
Time to pembrolizumab, median (mo)	17.0	12.2	33.7	19.0	19.9
EBV
Positive	15	0	1	14	0
Negative	15	10	3	0	2

DLBCL, diffuse large B-cell lymphoma; PMBCL, primary mediastinal B-cell lymphoma; NKTCL, NK/T-cell lymphoma; T-LBL, T-lymphoblastic lymphoma; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; IPI, International Prognostic Index; SCT, stem cell transplantation; EBV, Epstein-Barr virus.

Table 2.

EBV positivity and response to pembrolizumab treatment

	Total (n=30)	EBV
	Total (n=30)	Positive (n=15)	Negative (n=15)
Subtype
DLBCL	10	0	10
PMBCL	4	1	3
NKTCL	14	14	0
T-LBL	2	0	2
PDL1 expression
High	10	7	3
Low	7	5	2
No expression	5	0	5
Not evaluated	8	3	5
Response
Complete response	5	5	0
Partial response	2	2	0
Stable disease	0	0	0
Progressive disease	23	8	15

EBV, Epstein-Barr virus; DLBCL, diffuse large B-cell lymphoma; PMBCL, primary mediastinal B-cell lymphoma; NKTCL, NK/T-cell lymphoma; T-LBL, T-lymphoblastic lymphoma; PDL1, programmed cell death ligand 1.

Table 3.

Pembrolizumab in relapsed or refractory non-Hodgkin lymphoma

Study	Author	Disease	No.	Dose	Response	ORR
Case series	Kwong et al. [5]	NKTCL	7	100 mg every 3 wk	5 CR, 2 PR	100%
Case report	Lai et al. [9]	NKTCL	1	2 mg/kg every 3 wk	CR: alive without relapse	-
Case report	Chan et al. [10]	ALCL	1	2 mg/kg every 3 wk	CR	-
Case report	Chan et al. [13]	Double-hit lymphoma	1	Pembrolizumab 100 mg every 3 wk plus lenalidomide 15 mg daily	CR	-
Phase 1b trial	Zinzani et al. [11]	PMBCL	18	200 mg every 3 wk	2 CR, 5 PR	41% (7 of 17 evaluable patients)
Phase II	Ding et al. [23]	CLL (16) or Richter transformation (9)	25	200 mg every 3 wk	CLL: no response Transformed CLL: 2 CR/2 PR	CLL: 0% (0/16) Transformed CLL: 44% (4/9)
Phase II	Nastoupil et al. [12]	Follicular lymphoma	30	200 mg every 3 wk plus rituximab 375 mg/m² D1, 8, 15, 22	CR 60%	80%

ORR, overall response rate; NKTCL, NK/T-cell lymphoma; CR, complete response; PR, partial response; ALCL, anaplastic large cell lymphoma; PMBCL, primary mediastinal B-cell lymphoma; CLL, chronic lymphocytic leukemia.

Table 4.

PDL1 expression in non-Hodgkin lymphomas

	Cutoff (%)	DLBCL	PMBCL	MCL	CNS DLBCL	NKTCL	T-LBL	PTCL	SPTCL	AITL	EATL
Our study	≥ 50	2/18 (11)	4/6 (67)	0/2 (0)	0/3 (0)	15/28 (54)	0/8 (0)	2/7 (29)	2/2 (100)	1/1 (100)	0/1 (0)
Vranic et al. [15]	≥ 5	13/26 (50)	3/3 (100)	0/9 (0)	-	-	-	3/11 (28)	-	-	-
Menter et al. [14]	≥ 5	80/260 (31)	12/33 (36)	0/35 (0)	-	-	-	-	-	-	-
Kiyasu et al. [16]	≥ 30	132/1,253 (11)	-	-	-	-	-	-	-	-	-
Jo et al. [21]	≥ 5	-	-	-	-	63/79 (79)	-	-	-	-	-
Kim et al. [22]	≥ 10	-	-	-	-	41/73 (56)	-	-	-	-	-
Four et al. [20]	≥ 1	-	-	-	12/32 (38)	-	-	-	-	-	-

Values are presented as number (%). PDL1, programmed cell death ligand 1; DLBCL, diffuse large B-cell lymphoma; PMBCL, primary mediastinal B-cell lymphoma; MCL, mantle cell lymphoma; CNS, central nervous system; NKTCL, NK/T-cell lymphoma; T-LBL, T-lymphoblastic lymphoma; PTCL, peripheral T-cell lymphoma; SPTCL, subcutaneous panniculitis-like T-cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; EATL, enteropathy-associated T-cell lymphoma.

REFERENCES

1. Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970–6. Article PubMed
2. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800–8. Article PubMed PMC
3. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol. 2010;37:430–9. Article PubMed
4. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227–42. Article PubMed PMC PDF
5. Kwong YL, Chan TS, Tan D, Kim SJ, Poon LM, Mow B, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017;129:2437–42. Article PubMed
6. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68. Article PubMed PMC
7. Kim SJ, Choi JY, Hyun SH, Ki CS, Oh D, Ahn YC, et al. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. Lancet Haematol. 2015;2:e66–74. Article PubMed
8. Dako North America. PD-L1 IHC 22C3 pharmDx (package insert). Carpinteria, CA: Dako North America; 2015.
9. Lai J, Xu P, Jiang X, Zhou S, Liu A. Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report. BMC Cancer. 2017;17:507.Article PubMed PMC PDF
10. Chan TS, Khong PL, Kwong YL. Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety. Ann Hematol. 2016;95:1913–5. Article PubMed PDF
11. Zinzani PL, Ribrag V, Moskowitz CH, Michot JM, Kuruvilla J, Balakumaran A, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood. 2017;130:267–70. Article PubMed PMC
12. Nastoupil LJ, Westin J, Fowler N, Fanale M, Samaniego F, Oki Y, et al. High response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: interim results of an on open-label, phase II study. Hematol Oncol. 2017;35(Suppl 2):120–1. Article
13. Chan TS, Khong PL, Kwong YL. Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma. Ann Hematol. 2016;95:1917–8. Article PubMed PDF
14. Menter T, Bodmer-Haecki A, Dirnhofer S, Tzankov A. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. Hum Pathol. 2016;54:17–24. Article PubMed
15. Vranic S, Ghosh N, Kimbrough J, Bilalovic N, Bender R, Arguello D, et al. PD-L1 status in refractory lymphomas. PLoS One. 2016;11:e0166266Article PubMed PMC
16. Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood. 2015;126:2193–201. Article PubMed PMC
17. Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34:2690–7. Article PubMed PMC
18. Twa DD, Chan FC, Ben-Neriah S, Woolcock BW, Mottok A, Tan KL, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014;123:2062–5. Article PubMed
19. Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127:869–81. Article PubMed PMC
20. Four M, Cacheux V, Tempier A, Platero D, Fabbro M, Marin G, et al. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival. Hematol Oncol. 2017;35:487–96. Article PubMed
21. Jo JC, Kim M, Choi Y, Kim HJ, Kim JE, Chae SW, et al. Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type. Ann Hematol. 2017;96:25–31. Article PubMed PDF
22. Kim WY, Jung HY, Nam SJ, Kim TM, Heo DS, Kim CW, et al. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis. Virchows Arch. 2016;469:581–90. Article PubMed PDF
23. Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017;129:3419–27. Article PubMed PMC
24. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19:3462–73. Article PubMed PMC
25. Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Ponto G, et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol. 2016;24:392–7. Article PubMed PMC
26. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–33. Article PubMed
27. Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128:2489–96. Article PubMed
28. Chan TS, Luk TH, Lau JS, Khong PL, Kwong YL. Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity. Ann Hematol. 2017;96:647–51. Article PubMed PDF
29. Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34:3733–9. Article PubMed PMC
30. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35:2125–32. Article PubMed PMC

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Dismal Outcome of EBV-Positive Nodal T/NK-Cell Lymphoma: A Multicenter Retrospective Study
Satoshi Ichikawa, Noriko Fukuhara, Yuna Katsuoka, Yuki Ishizawa, Kosuke Kamata, Masahiko Fukatsu, Takayo Nagao, Kazunori Murai, Hisayuki Yokoyama, Yoshiko Tamai, Takayuki Ikezoe, Ryo Ichinohasama, Shigeki Ito, Naoto Takahashi, Hideo Harigae
Clinical Lymphoma Myeloma and Leukemia.2026; 26(3): e376. CrossRef
Epstein-Barr virus-associated tumors: commonalities in pathogenesis and the tumor immune microenvironment
Xiyi Wang, Dongmei Hu, Renqin Li, Wenjun Liao, Chao Li, Qiuhan Liu, Jiayao Li, Qiaohua Li, Wenpei Guo, Liyang Wang, Shichuan Zhang, Yue Zhao
Frontiers in Immunology.2026;[Epub] CrossRef
Anti-PD-1 antibody (Tislelizumab) combined with gemcitabine and oxaliplatin for extranodal NK/T-cell lymphoma failing asparaginase: A multicenter phase II trial
Kaiyang Ding, Hailing Liu, Lixia Sheng, Jie Ma, Xiaohui Zhang, Hongming Huang, Wei Shi, Hongling Peng, Lei Cao, Wei Wu, Jianyong Li, Lei Fan
European Journal of Cancer.2025; 214: 115155. CrossRef
MiR-340-5p regulates PD-L1 and predicts pembrolizumab response in extranodal NK/T-cell lymphoma
Kyung Ju Ryu, Haein Ji, Bon Park, Sang Eun Yoon, Junhun Cho, Won Seog Kim, Hyeon Ho Kim, Seok Jin Kim
Scientific Reports.2025;[Epub] CrossRef
Tumor‐Associated Sympathetic Nerves Promote the Progression of Epstein‐Barr Virus‐Positive Diffuse Large B‐Cell Lymphoma
Silan Huang, Dexin Lei, Linbin Yang, Aiwei Bi, Yanlou Wang, Peng Zhang, Dongyu Zhuang, Honglian Liu, Qingqing Cai, Man Nie, Yi Xia
Advanced Science.2025;[Epub] CrossRef
Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma
Seok Jin Kim, Jing Quan Lim, Sang Eun Yoon, Deok-Hwan Yang, Ji Hyun Lee, Sung Yong Oh, Yoon Seok Choi, Seong Hyun Jeong, Min Kyoung Kim, Sung Nam Lim, Junhun Cho, Bon Park, Kyung Ju Ryu, Seunghyun Choi, Yoon Park, Kerry May Huifen Lim, Nur Ayuni Binte Muh
Blood.2025; 146(2): 155. CrossRef
Viral oncogenesis and immune remodeling: Decoding the therapeutic potential of immune checkpoint inhibitors in virus-associated cancers
Lihua Qi, Bai Hu, Canhui Cao, Ting Peng, Miaochun Xu, Shiyi Liu, Yashi Xu, Xiaojie Liu, Wencheng Ding, Li Li, Shitong Lin
Biomedicine & Pharmacotherapy.2025; 191: 118515. CrossRef
Anti-PD-1 therapy achieves favorable outcome in gastric cancer combined with chronic hepatitis B
Lingyan Wang, Fei Yang, Qinhui Dong, Tao-Hsin Tung, Junyan Ye, Kaili Cen, Yupei Yang, Jingjing Xie, Qunyi Guo
BMC Cancer.2025;[Epub] CrossRef
Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics
Joshua M. L. Casan, Xiao Jing Ong, Carrie van der Weyden, Costas K. Yannakou, Joe Zhu, Criselle D’Souza, Paul Neeson, H. Miles Prince
Journal of Personalized Medicine.2025; 15(11): 560. CrossRef
Tislelizumab and Radiation Therapy in Low-Risk Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Phase II Study Protocol
Jia-Ying Li, Shu-Nan Qi, Chen Hu, Xin Liu, Yong Yang, Tao Wu, Rong Zheng, Xiao-Li Feng, Xiao-Guang Ni, Feng-Yan Jin, Yu-Qin Song, Wei-Ping Liu, Sheng-Yu Zhou, Ye-Xiong Li
Future Oncology.2024; 20(5): 245. CrossRef
Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review
Mohammad Sadegh Fallahi, Nasibeh Zerangian, Atousa Ghorbani, Gisou Erabi, Melika Shirali, Elaheh Shabani, Foad Rommasi, Mahsa Mohammadi Najafabadi, Shima Karbasi, Samaneh Toutounchian, Ramin Ahangar-Sirous, Ava Motaghy, Mahsa Heidari, Niloofar Deravi
Current Cancer Therapy Reviews.2024; 20(1): 53. CrossRef
The IPTA Nashville consensus conference on post‐transplant lymphoproliferative disorders after solid organ transplantation in children: IV‐consensus guidelines for the management of post‐transplant lymphoproliferative disorders in children and adolescents
Upton D. Allen, Arnaud G. L'Huillier, Catherine M. Bollard, Thomas G. Gross, Robert J. Hayashi, Britta Höcker, Britta Maecker‐Kolhoff, Stephen D. Marks, George Vincent Mazariegos, Francoise Smets, Ralf U. Trappe, Gary Visner, Richard E. Chinnock, Patrizia
Pediatric Transplantation.2024;[Epub] CrossRef
Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea
Ji Yun Lee, Ji Hyun Kwon, Joon Young Hur, Jun Ho Yi, Ji Hyun Lee, Hyungwoo Cho, Young Rok Do, Jae-Cheol Jo, Hye Jin Kang, Yougil Koh, Won Sik Lee, Sung Nam Lim, Sang Eun Yoon, Seok Jin Kim, Jeong-Ok Lee
Cancer Research and Treatment.2024; 56(2): 681. CrossRef
Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK/T cell lymphoma
Wendy W. L. Lee, Jing Quan Lim, Tiffany P. L. Tang, Daryl Tan, Ser Mei Koh, Kia Joo Puan, Liang Wei Wang, Jackwee Lim, Kim Peng Tan, Wee Joo Chng, Soon Thye Lim, Choon Kiat Ong, Olaf Rotzschke
Frontiers in Immunology.2024;[Epub] CrossRef
Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art
Magda Zanelli, Valentina Fragliasso, Paola Parente, Alessandra Bisagni, Francesca Sanguedolce, Maurizio Zizzo, Giuseppe Broggi, Stefano Ricci, Andrea Palicelli, Moira Foroni, Fabrizio Gozzi, Pietro Gentile, Andrea Morini, Nektarios Koufopoulos, Rosario Ca
International Journal of Molecular Sciences.2024; 25(12): 6447. CrossRef
EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and management
Luis Malpica, Mario L. Marques‐Piubelli, Brady E. Beltran, Julio C. Chavez, Roberto N. Miranda, Jorge J. Castillo
American Journal of Hematology.2024; 99(10): 2002. CrossRef
Multiplexed Spatial Profiling of Hodgkin Reed–Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma
Maryam Pourmaleki, Caitlin J. Jones, Sabrina D. Mellinghoff, Brian D. Greenstein, Priyadarshini Kumar, Miguel Foronda, Daniel A. Navarrete, Carl Campos, Mikhail Roshal, Nikolaus Schultz, Sohrab P. Shah, Andrea Schietinger, Nicholas D. Socci, Travis J. Hol
Clinical Cancer Research.2024; 30(17): 3881. CrossRef
PD-1 inhibitors plus chemotherapy for refractory EBV-positive DLBCL: a retrospective analysis
Youli Li, Yonghe Wu, Sufen Cao, Baohua Yu, Qunling Zhang, Zuguang Xia, Junning Cao, Fangfang Lv, Guang-Liang Chen
Blood Research.2024;[Epub] CrossRef
The ‘Oma’s of the Gammas—Cancerogenesis by γ-Herpesviruses
Anwesha Banerjee, Debashree Dass, Soumik Mukherjee, Mollina Kaul, R. Harshithkumar, Parikshit Bagchi, Anupam Mukherjee
Viruses.2024; 16(12): 1928. CrossRef
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma
Mwanasha H. Merrill, Parastoo B. Dahi, Robert A. Redd, Mikaela M. McDonough, Yi-Bin Chen, Zachariah DeFilipp, Alex F. Herrera, David C. Fisher, Ann S. LaCasce, Oreofe O. Odejide, Samuel Y. Ng, Caron A. Jacobson, Reid W. Merryman, Austin I. Kim, Yago L. Ni
Blood.2023; 142(7): 621. CrossRef
The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis
Yanxia He, Yan Gao, Liqin Ping, Haixia He, Cheng Huang, Bing Bai, Xiaoxiao Wang, Zhiming Li, Qingqing Cai, Yuhua Huang, Xueyi Pan, Wenbin Zeng, Yanan Liu, Huiqiang Huang
Journal of Cancer Research and Clinical Oncology.2023; 149(5): 2017. CrossRef
Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment
Chunlan Zhang, Leiming Wang, Caigang Xu, Heng Xu, Yu Wu
Frontiers in Pharmacology.2023;[Epub] CrossRef
The Role of NK Cells in EBV Infection and Related Diseases: Current Understanding and Hints for Novel Therapies
Maria G. Desimio, Daniela A. Covino, Beatrice Rivalta, Caterina Cancrini, Margherita Doria
Cancers.2023; 15(6): 1914. CrossRef
Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer
Jie Zhou, Guanming Chen, Jiuling Wang, Bo Zhou, Xuemin Sun, Jinsong Wang, Shu Tang, Xiangju Xing, Xiaofei Hu, Yang Zhao, Yu Peng, Wenjiong Shi, Tingting Zhao, Yuzhang Wu, Hanbing Zhong, Ni Hong, Zhihua Ruan, Yi Zhang, Wenfei Jin
Oncogenesis.2023;[Epub] CrossRef
Education and Empowering Special Forces to Eradicate Secret Defectors: Immune System-Based Treatment Approaches for Mature T- and NK-Cell Malignancies
Till Braun, Alexandra Schrader
Cancers.2023; 15(9): 2532. CrossRef
Efficacy of Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Narrative Review
Sarah Perdikis-Prati, Semira Sheikh, Antonin Bouroumeau, Noémie Lang
Biomedicines.2023; 11(6): 1720. CrossRef
First‐line immunotherapy with anti‐PD‐1 antibody for extranodal NK/T‐cell lymphoma: A retrospective study
Xiaoxiao Wang, Lei Wen, Jing Liao, Yanfen Feng, Yuhong Li, Zhaoming Zhou, Cheng Zhou, Huiqiang Huang
British Journal of Haematology.2023; 202(4): 812. CrossRef
Advances and challenges of immunotherapies in NK/T cell lymphomas
Ling He, Na Chen, Lei Dai, Xingchen Peng
iScience.2023; 26(11): 108192. CrossRef
Adult's Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis: A case report
Yi Sun, Han Yao, Xiaofeng Yu, Yunzhao Chen, Chen Chai
Clinical Case Reports.2023;[Epub] CrossRef
Serious consequences of Epstein‐Barr virus infection: Hemophagocytic lymphohistocytosis
Lingyue Xu, Xiaofang Guo, Hongzai Guan
International Journal of Laboratory Hematology.2022; 44(1): 74. CrossRef
Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine
Ka-Hei (Murphy) Sun, Yin-Ting (Heylie) Wong, Ka-Man (Carmen) Cheung, Carmen (Michelle) Yuen, Yun-Tat (Ted) Chan, Wing-Yan (Jennifer) Lai, Chun (David) Chao, Wing-Sum (Katie) Fan, Yuen-Kiu (Karen) Chow, Man-Fai Law, Ho-Chi (Tommy) Tam
Diagnostics.2022; 12(2): 409. CrossRef
The Epstein-Barr Virus Hacks Immune Checkpoints: Evidence and Consequences for Lymphoproliferative Disorders and Cancers
Alison Felipe Bordini Biggi, Deilson Elgui de Oliveira
Biomolecules.2022; 12(3): 397. CrossRef
Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
Xi Chen, Wanchun Wu, Wenwen Wei, Liqun Zou
Frontiers in Pharmacology.2022;[Epub] CrossRef
EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk‐stratification, and management
Luis Malpica, Mario L. Marques‐Piubelli, Brady E. Beltran, Julio C. Chavez, Roberto N. Miranda, Jorge J. Castillo
American Journal of Hematology.2022; 97(7): 951. CrossRef
Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions
John C. Reneau, Polina Shindiapina, Zachary Braunstein, Youssef Youssef, Miguel Ruiz, Saira Farid, Walter Hanel, Jonathan E. Brammer
Journal of Clinical Medicine.2022; 11(10): 2699. CrossRef
Cellular Origins and Pathogenesis of Gastrointestinal NK- and T-Cell Lymphoproliferative Disorders
Susan Swee-Shan Hue, Siok-Bian Ng, Shi Wang, Soo-Yong Tan
Cancers.2022; 14(10): 2483. CrossRef
Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials
Yang Xu, Ping Li, Yang Liu, Dijia Xin, Wen Lei, Aibin Liang, Weidong Han, Wenbin Qian
Cancer Communications.2022; 42(6): 493. CrossRef
Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
N Nora Bennani, Hyo Jin Kim, Levi D Pederson, Pamela J Atherton, Ivana N Micallef, Gita Thanarajasingam, Grzegorz S Nowakowski, Thomas Witzig, Andrew L Feldman, Stephen M Ansell
Journal for ImmunoTherapy of Cancer.2022; 10(6): e004984. CrossRef
Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma
Felix Marsh-Wakefield, Angela L Ferguson, Ken Liu, Cositha Santhakumar, Geoffrey McCaughan, Umaimainthan Palendira
Therapeutic Advances in Medical Oncology.2022;[Epub] CrossRef
Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management
Eric Tse, Christopher P. Fox, Alexander Glover, Sang Eun Yoon, Won Seog Kim, Yok-Lam Kwong
Seminars in Hematology.2022; 59(4): 198. CrossRef
Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma
Seok Jin Kim, Kyung Ju Ryu, Bon Park, Sang Eun Yoon, Junhun Cho, Yoon Park, Won Seog Kim
Cancers.2022; 14(22): 5618. CrossRef
Characterization of Artificial Pneumothorax-Unrelated Pyothorax-Associated Lymphoma
Guang-Liang Chen, Zu-Guang Xia, Jia Jin, Bao-Hua Yu, Junning Cao, Amir Radfar
Journal of Oncology.2021; 2021: 1. CrossRef
Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review
Lee S. Nguyen, Lisa Raia, Bénédicte Lebrun-Vignes, Joe-Elie Salem
Frontiers in Pharmacology.2021;[Epub] CrossRef
Pulmonary Lymphoepithelioma-Like Carcinoma Treated with Immunotherapy or Chemotherapy: A Single Institute Experience
Yang Fu, Yue Zheng, Pei-Pei Wang, Yue-Yun Chen, Zhen-Yu Ding
OncoTargets and Therapy.2021; Volume 14: 1073. CrossRef
EBV et immunodépression
Y. Dieudonne, M. Martin, A.-S. Korganow, D. Boutboul, A. Guffroy
La Revue de Médecine Interne.2021; 42(12): 832. CrossRef
PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma
Joshua W. D. Tobin, Karolina Bednarska, Ashlea Campbell, Colm Keane
Cells.2021; 10(5): 1152. CrossRef
NK-/T-cell lymphomas
Hua Wang, Bi-bo Fu, Robert Peter Gale, Yang Liang
Leukemia.2021; 35(9): 2460. CrossRef
The role of EBV in haematolymphoid proliferations: emerging concepts relevant to diagnosis and treatment
Emad Ababneh, Anas M Saad, Genevieve M Crane
Histopathology.2021; 79(4): 451. CrossRef
Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study
Won Seog Kim, Yasuhiro Oki, Seok Jin Kim, Sang Eun Yoon, Kirit M. Ardeshna, Yi Lin, Jia Ruan, Pierluigi Porcu, Jonathan E. Brammer, Eric D. Jacobsen, Dok Hyun Yoon, Cheolwon Suh, Felipe Suarez, John Radford, Lihua E. Budde, Jin Seok Kim, Emmanuel Bachy, H
Annals of Hematology.2021; 100(10): 2529. CrossRef
The Role of Epstein–Barr virus-encoded Latent Membrane Proteins in Host Immune Escape
Yuanyuan Jiang, Yuan Ding, Shuzhen Liu, Bing Luo
Future Virology.2021; 16(8): 565. CrossRef
EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 1)
Magda Zanelli, Francesca Sanguedolce, Andrea Palicelli, Maurizio Zizzo, Giovanni Martino, Cecilia Caprera, Valentina Fragliasso, Alessandra Soriano, Luca Valle, Stefano Ricci, Alberto Cavazza, Francesco Merli, Stefano A. Pileri, Stefano Ascani
Cancers.2021; 13(18): 4578. CrossRef
Chemorefractory extranodal nasal-type natural-killer/T-cell lymphoma with great response to pembrolizumab in a young patient: a case report
Fatemeh Adabifirouzjaei, Bharam Khazai, Ghazaleh Azami, Ghazaleh Shoja-e-Razavi
Journal of Medical Case Reports.2021;[Epub] CrossRef
Clinical and Therapeutic Implications of Epstein–Barr Virus in HIV-Related Lymphomas
Miriam Verdu-Bou, Gustavo Tapia, Agueda Hernandez-Rodriguez, Jose-Tomas Navarro
Cancers.2021; 13(21): 5534. CrossRef
Regulation of the Immune Checkpoint Indoleamine 2,3-Dioxygenase Expression by Epstein–Barr Virus
Leila Sawada, Antonio Carlos Rosário Vallinoto, Igor Brasil-Costa
Biomolecules.2021; 11(12): 1792. CrossRef
Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors
Alejandro Olivares-Hernández, Luis Figuero-Pérez, José Pablo Miramontes-González, Álvaro López-Gutiérrez, Rogelio González-Sarmiento, Juan Jesús Cruz-Hernández, Emilio Fonseca-Sánchez
Life.2021; 11(12): 1400. CrossRef
EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk‐stratification and management
Brady E. Beltran, Denisse Castro, Sally Paredes, Roberto N. Miranda, Jorge J. Castillo
American Journal of Hematology.2020; 95(4): 435. CrossRef
Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression
Junhun Cho, Seok Jin Kim, Woong-Yang Park, Jinho Kim, Jeongmin Woo, Gahyun Kim, Sang Eun Yoon, Young Hyeh Ko, Won Seog Kim
Modern Pathology.2020; 33(4): 603. CrossRef
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation
Matthew J. Frigault, Philippe Armand, Robert A. Redd, Erin Jeter, Reid W. Merryman, Kimberly C. Coleman, Alex F. Herrera, Parastoo Dahi, Yago Nieto, Ann S. LaCasce, David C. Fisher, Samuel Y. Ng, Oreife O. Odejide, Arnold S. Freedman, Austin I. Kim, Jenni
Blood Advances.2020; 4(1): 122. CrossRef
Checkmate for EBV-HLH
Nader Kim El-Mallawany, Kenneth L. McClain
Blood.2020; 135(11): 782. CrossRef
CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma
Yue Song, Wei Song, Zhaoming Li, Wenting Song, Yibo Wen, Jiwei Li, Qingxin Xia, Mingzhi Zhang
Frontiers in Oncology.2020;[Epub] CrossRef
Stage IV natural killer/T-cell lymphoma with chronic active Epstein–Barr virus, treated with pembrolizumab and TCRαβ-depleted haploidentical hematopoietic stem cell transplantation
Yeong Eun Kim, Hyery Kim, Juhee Shin, So Yoon Min, Sung Han Kang, Jin Kyung Suh, Kyung-Nam Koh, Ho Joon Im
Leukemia & Lymphoma.2020; 61(9): 2250. CrossRef
Virus-Specific T Cells for the Treatment of Malignancies—Then, Now, and the Future
Sandhya Sharma, Wingchi K Leung, Helen E Heslop
Current Stem Cell Reports.2020; 6(2): 17. CrossRef
The roles of programmed death ligand 1 in virus-associated cancers
Morvarid Golrokh Mofrad, Donya Taghizadeh Maleki, Ebrahim Faghihloo
Infection, Genetics and Evolution.2020; 84: 104368. CrossRef
Immune-Checkpoint Blockade Therapy in Lymphoma
Ayumi Kuzume, SungGi Chi, Nobuhiko Yamauchi, Yosuke Minami
International Journal of Molecular Sciences.2020; 21(15): 5456. CrossRef
Multiplex immunohistochemistry in lymphoma pathology: a research tool for study of the immune microenvironment
Matthew Pugh, Ayse U. Akarka, Kelly Hunter, Stefan Dojcinov, Teresa Marafioti
Diagnostic Histopathology.2020; 26(9): 407. CrossRef
Targeting immune checkpoints in hematological malignancies
Basit Salik, Mark J. Smyth, Kyohei Nakamura
Journal of Hematology & Oncology.2020;[Epub] CrossRef
Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas
Yonggang Pei, Josiah H. Y. Wong, Erle S. Robertson
Cancers.2020; 12(9): 2565. CrossRef
Immunology of EBV-Related Lymphoproliferative Disease in HIV-Positive Individuals
Polina Shindiapina, Elshafa H. Ahmed, Anna Mozhenkova, Tamrat Abebe, Robert A. Baiocchi
Frontiers in Oncology.2020;[Epub] CrossRef
Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
Ji-Yoon Noh, Huiyun Seo, Jungwoon Lee, Haiyoung Jung
International Journal of Molecular Sciences.2020; 21(21): 8000. CrossRef
EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas
Danielle L.V. Maracaja, Vidya Puthenpura, Salley G. Pels, Dennis P. O’Malley, Jeffrey L. Sklar, Karin E. Finberg, Mina L. Xu
Applied Immunohistochemistry & Molecular Morphology.2020; 28(10): 725. CrossRef
Current Immunotherapy Approaches in Non-Hodgkin Lymphomas
Robert Pytlik, Kamila Polgarova, Jana Karolova, Pavel Klener
Vaccines.2020; 8(4): 708. CrossRef
Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review
Zheng Yan, Shuna Yao, Yanyan Liu, Jianbo Zhang, Peng Li, Haiying Wang, Junfeng Chu, Shuang Zhao, Zhihua Yao
Frontiers in Oncology.2020;[Epub] CrossRef
Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study
Seok Jin Kim, Jing Quan Lim, Yurike Laurensia, Junhun Cho, Sang Eun Yoon, Ji Young Lee, Kyung Ju Ryu, Young Hyeh Ko, Youngil Koh, Duck Cho, Soon Thye Lim, Marie Beck Enemark, Francesco D’Amore, Mette Bjerre, Choon Kiat Ong, Won Seog Kim
Blood.2020; 136(24): 2754. CrossRef
Pembrolizumab

Reactions Weekly.2019; 1754(1): 273. CrossRef
Immune checkpoint inhibitors in the treatment of virus-associated cancers
Peipei Gao, Cordelle Lazare, Canhui Cao, Yifan Meng, Ping Wu, Wenhua Zhi, Shitong Lin, Juncheng Wei, Xiaoyuan Huang, Ling Xi, Gang Chen, Junbo Hu, Ding Ma, Peng Wu
Journal of Hematology & Oncology.2019;[Epub] CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas

Cancer Res Treat. 2019;51(2):611-622. Published online July 20, 2018

DOI: https://doi.org/10.4143/crt.2018.191

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas

Fig. 1. Clinical outcome and treatment cycles of NK/T-cell lymphoma (NKTCL), primary mediastinal B-cell lymphoma (PMBCL), diffuse large B-cell lymphoma (DLBCL), and T-lymphoblastic lymphoma (T-LBL). EBV, Epstein-Barr virus; PDL1, programmed cell death ligand 1; H, high; CR, complete response; NA, not available; L, low; PR, partial response; PD, progressive disease.

Fig. 2. (A) Comparison of programmed cell death ligand 1 (PDL1) expression in 76 patients with non-Hodgkin lymphoma shows different frequencies of high (≥ 50% of PDL1-positive tumor cells), low (1%-49% of PDL1-positive tumor cells), and no expression. High PDL1 expression is more frequent in NK/T-cell lymphoma (NKTCL; 15/28, 54%) and primary mediastinal B-cell lymphoma (PMBCL; 4/6, 67%) than in peripheral T-cell lymphoma (PTCL; 2/7, 28%), diffuse large B-cell lymphoma (DLBCL; 2/18, 11%), and T-lymphoblastic lymphoma (T-LBL; 0/8, 0%). No case of PDL1 high expression is observed in primary central nervous system diffuse large B-cell lymphoma (CNS DLBCL; 0/3), mantle cell lymphoma (MCL, 0/2), or enteropathy-associated T-cell lymphoma (EATL; 0/1). However, subcutaneous panniculitis-like T-cell lymphoma (SPTCL; 2/2) and angioimmunoblastic T-cell lymphoma (AITL; 1/1) show high PDL1 expression. (B) Epstein-Barr virus (EBV)–positive non-Hodgkin lymphoma (NHL) shows a significantly higher proportion of high PDL1 expression (18/32, 56%) than EBV-negative NHL (4/38, 11%, p < 0.001).

Fig. 3. (A) Immunohistochemistry for programmed cell death ligand 1 (PDL1) shows ≥ 50% of tumor cells positively stained (brown membranous staining) in a case of extranodal NK/T-cell lymphoma (top left); decrease in blood Epstein-Barr virus (EBV) DNA level after pembrolizumab treatment (top right); decrease in fluorodeoxyglucose (FDG) uptake in liver and spleen after pembrolizumab treatment (bottom). (B) Immunohistochemistry for PDL1 shows < 1% of tumor cells positively stained in a case of extranodal NK/T-cell lymphoma (top left); increase in blood EBV DNA level even after pembrolizumab treatment (top right); increase in the extent and intensity of FDG uptake in a soft tissue mass in an extremity after pembrolizumab treatment (bottom).

Fig. 1.

Fig. 2.

Fig. 3.

Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas

	Total (n=30)	DLBCL (n=10)	PMBCL (n=4)	NKTCL (n=14)	T-LBL (n=2)
Age (yr)
≤ 60	22	7	4	9	2
> 60	8	3	0	5	0
Sex
Male	21	7	1	11	2
Female	9	3	3	3	0
Performance status
ECOG 0/1	9	1	3	4	1
ECOG ≥ 2	21	9	1	10	1
Stage
I/II	2/2	0/0	1/1	2	0
III/IV	0/26	0/10	0/2	12	2
No. of extranodal involvements
0/1	5	1	2	2	0
≥ 2	25	9	2	12	2
Serum LDH
Normal	10	2	1	5	0
Increased	20	8	3	9	2
IPI
Low/Low-intermediate	4/2	0/1	2/0	2/0	0/1
High-intermediate/High	8/16	1/8	1/1	5/7	1/0
No. of previous treatments, median (range)	4 (1-10)	5 (2-10)	4 (3-6)	3 (1-7)	2 (2-3)
Previous SCT	14	3	2	6	2
Autologous	9	3	2	4	0
Allogeneic	4	0	0	2	1
Both	1	0	0	0	1
Time to pembrolizumab, median (mo)	17.0	12.2	33.7	19.0	19.9
EBV
Positive	15	0	1	14	0
Negative	15	10	3	0	2

	Total (n=30)	EBV
	Total (n=30)	Positive (n=15)	Negative (n=15)
Subtype
DLBCL	10	0	10
PMBCL	4	1	3
NKTCL	14	14	0
T-LBL	2	0	2
PDL1 expression
High	10	7	3
Low	7	5	2
No expression	5	0	5
Not evaluated	8	3	5
Response
Complete response	5	5	0
Partial response	2	2	0
Stable disease	0	0	0
Progressive disease	23	8	15

Study	Author	Disease	No.	Dose	Response	ORR
Case series	Kwong et al. [5]	NKTCL	7	100 mg every 3 wk	5 CR, 2 PR	100%
Case report	Lai et al. [9]	NKTCL	1	2 mg/kg every 3 wk	CR: alive without relapse	-
Case report	Chan et al. [10]	ALCL	1	2 mg/kg every 3 wk	CR	-
Case report	Chan et al. [13]	Double-hit lymphoma	1	Pembrolizumab 100 mg every 3 wk plus lenalidomide 15 mg daily	CR	-
Phase 1b trial	Zinzani et al. [11]	PMBCL	18	200 mg every 3 wk	2 CR, 5 PR	41% (7 of 17 evaluable patients)
Phase II	Ding et al. [23]	CLL (16) or Richter transformation (9)	25	200 mg every 3 wk	CLL: no response Transformed CLL: 2 CR/2 PR	CLL: 0% (0/16) Transformed CLL: 44% (4/9)
Phase II	Nastoupil et al. [12]	Follicular lymphoma	30	200 mg every 3 wk plus rituximab 375 mg/m² D1, 8, 15, 22	CR 60%	80%

	Cutoff (%)	DLBCL	PMBCL	MCL	CNS DLBCL	NKTCL	T-LBL	PTCL	SPTCL	AITL	EATL
Our study	≥ 50	2/18 (11)	4/6 (67)	0/2 (0)	0/3 (0)	15/28 (54)	0/8 (0)	2/7 (29)	2/2 (100)	1/1 (100)	0/1 (0)
Vranic et al. [15]	≥ 5	13/26 (50)	3/3 (100)	0/9 (0)	-	-	-	3/11 (28)	-	-	-
Menter et al. [14]	≥ 5	80/260 (31)	12/33 (36)	0/35 (0)	-	-	-	-	-	-	-
Kiyasu et al. [16]	≥ 30	132/1,253 (11)	-	-	-	-	-	-	-	-	-
Jo et al. [21]	≥ 5	-	-	-	-	63/79 (79)	-	-	-	-	-
Kim et al. [22]	≥ 10	-	-	-	-	41/73 (56)	-	-	-	-	-
Four et al. [20]	≥ 1	-	-	-	12/32 (38)	-	-	-	-	-	-

Table 1. Clinical characteristics of patients at the time of pembrolizumab treatment

Table 2. EBV positivity and response to pembrolizumab treatment

Table 3. Pembrolizumab in relapsed or refractory non-Hodgkin lymphoma

Table 4. PDL1 expression in non-Hodgkin lymphomas